Bendamustine plus rituximab in newly‐diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO).

Authors :: Laribi, Kamel
Poulain, Stéphanie
Willems, Lise
Merabet, Fatiha
Le Calloch, Ronan
Eveillard, Jean R.
Herbaux, Charles
Roos‐Weil, Damien
Chaoui, Driss
Roussel, Xavier
Tricot, Sabine
Dupuis, Jehan
Dartigeas, Caroline
Bareau, Benoit
Bene, Marie C.
Baugier de Materre, Alix
Leblond, Véronique
Source :: British Journal of Haematology; Jul2019, Vol. 186 Issue 1, p146-149, 4p, 1 Chart, 1 Graph
Publication Year :: 2019
Abstract: The article focuses on study that evaluated the efficacy and safety of bendamustine plus rituximab (BR) in symptomatic untreated patients with Waldenstr€om macroglobulinaemia (WM). It mentions the results like a patient developed myelodysplastic syndrome after BR initiation and other developed breast cancer.

Full Text Access

Tools